Sarepta Therapeutics | SRPT - 营业费用



金融业
股票价格
USD
资产
USD 3.18B
现金及等价物
USD 464.45M
销售成本
USD 109.46M
流动资产
USD 2.31B
流动负债
USD 499.16M
债务
USD 1.04B
EBIT
USD 358.43M
EBITDA
USD -252.2M
员工
1.37K
EPS每股收益
USD 3.16
股本和储备
USD 1.51B
销售毛利
USD 621.34M
债务利息支出
USD 20.84M
利息收入
USD 8.74M
贷款资金
USD 838.16M
市值
USD 1.59B
净收入
USD 330.96M
营业费用
USD 372.37M
营业利润
USD 358.43M
普通股股本
USD 105.57M
PE价格收益
27.27
税前利润
USD 343.17M
销售收入
USD 730.8M
销售和管理费用
USD 54.03M
股票
USD 1B
贸易债权人
USD 70.38M
应收帐款人
USD 547.91M


营业费用 更改 日
Acadia Pharmaceuticals USD 272.68M 6.08M 2026-03
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Alnylam Pharmaceuticals USD 898.54M 66.78M 2026-03
Amgen USD 4.78B 1.12B 2026-03
BioCryst Pharmaceuticals USD -553.84M 700.01M 2026-03
Biogen USD 1.96B 69.6M 2026-03
BioMarin Pharmaceutical USD 636.56M 39.61M 2026-03
Capricor Therapeutics USD 29.16M 2.87M 2025-12
Daiichi Sankyo JPY 468.57B 15.34B 2025-12
Eli Lilly USD 10.02B 285M 2026-03
Esperion Therapeutics USD 83.21M 14.06M 2025-12
Gilead Sciences USD 23.52B 18.55B 2026-03
Incyte USD 5.62B 4.5B 2026-03
Insmed USD 506.24M 7.31M 2026-03
Ionis Pharmaceuticals USD 364M 54M 2026-03
Moderna USD 1.78B 242M 2026-03
Nektar Therapeutics USD 40.9M 44.19M 2025-12
Neurocrine Biosciences USD 599.9M 22.3M 2026-03
Novavax USD 126.2M 23.62M 2025-12
Pfizer USD 90.1B 77.19B 2026-03
PTC Therapeutics USD 226.66M 19.64M 2026-03
Regeneron Pharmaceuticals USD 31.42B 28.44B 2026-03
Roche Holding CHF 21.01B 10.84B 2025-12
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Sanofi EUR 9.31B 1.2B 2026-03
Sarepta Therapeutics USD 372.37M 480.65M 2026-03
Tectonic Therapeutic USD 21.52M 374K 2025-12
Ultragenyx Pharmaceutical USD 305M 16M 2026-03
Vertex Pharmaceuticals USD 1.85B 78.6M 2026-03